|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Naggar AK, Chan JKC, Grandis JR, Takata
T and Slootweg PJ: WHO Classification of Head and Neck Tumours. WHO
Classification of Tumours. 9. 4th edition. IARC Publications; Lyon:
pp. 65–69. 2017
|
|
3
|
Blanchard P, Lee A, Marguet S, Leclercq J,
Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, et al:
Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An
update of the MAC-NPC meta-analysis. Lancet Oncol. 16:645–655.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee AW, Ng WT, Pan JJ, Poh SS, Ahn YC,
AlHussain H, Corry J, Grau C, Grégoire V Harrington KJ, et al:
International guideline for the delineation of the clinical target
volumes (CTV) for nasopharyngeal carcinoma. Radiother Oncol.
126:25–36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK,
Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE and
Ensley JF: Chemoradiotherapy versus radiotherapy in patients with
advanced nasopharyngeal cancer: Phase III randomized Intergroup
study 0099. J Clin Oncol. 16:1310–1317. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen QY, Wen YF, Guo L, Liu H, Huang PY,
Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, et al: Concurrent
chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal
carcinoma: Phase III randomized trial. J Natl Cancer Inst.
103:1761–1770. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chan AT, Leung SF, Ngan RK, Teo PM, Lau
WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, et al: Overall
survival after concurrent cisplatin-radiotherapy compared with
radiotherapy alone in locoregionally advanced nasopharyngeal
carcinoma. J Natl Cancer Inst. 97:536–539. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee AW, Ng WT, Hung WM, Choi CW, Tung R,
Ling YH, Cheng PT, Yau TK, Chang AT, Leung SK, et al: Major late
toxicities after conformal radiotherapy for nasopharyngeal
carcinoma-patient- and treatment-related risk factors. Int J Radiat
Oncol Biol Phys. 73:1121–1128. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zeng L, Tian YM, Sun XM, Chen CY, Han F,
Xiao WW, Deng XW and Lu TX: Late toxicities after
intensity-modulated radiotherapy for nasopharyngeal carcinoma:
Patient and treatment-related risk factors. Br J Cancer. 110:49–54.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang TL, Chien CY, Tsai WL, Liao KC, Chou
SY, Lin HC, Dean Luo S, Lee TF, Lee CH and Fang FM: Long-term late
toxicities and quality of life for survivors of nasopharyngeal
carcinoma treated with intensity-modulated radiotherapy versus
non-intensity-modulated radiotherapy. Head Neck. 38 (Suppl
1):E1026–E1032. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao C, Miao JJ, Hua YJ, Wang L, Han F, Lu
LX, Xiao WW, Wu HJ, Zhu MY, Huang SM, et al: Locoregional control
and mild late toxicity after reducing target volumes and radiation
doses in patients with locoregionally advanced nasopharyngeal
carcinoma treated with induction chemotherapy (IC) followed by
concurrent chemoradiotherapy: 10-year results of a phase 2 study.
Int J Radiat Oncol Biol Phys. 104:836–844. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition.
Springer; Paris: 2010, Available from. http://www.springer.com/medicine/surgery/book/978-0-387-88440-0
|
|
14
|
Head and Neck Cancer Study Group (HNCSG),
. Monden N, Asakage T, Kiyota N, Homma A, Matsuura K, Hanai N,
Kodaira T, Zenda S, Fujii H, et al: A review of head and neck
cancer staging system in the TNM classification of malignant tumors
(eight edition). Jpn J Clin Oncol. 49:589–595. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
ICRU Report 50, . Prescribing, Recording,
and Reporting Photon Beam Therapy. International Commission on
Radiation Units and Measurements; Bethesda, MD: 1993
|
|
16
|
ICRU Report 62, . Prescribing, Recording,
and Reporting Photon Beam Therapy (Supplement to ICRU Report 50).
International Commission on Radiation Units and Measurements;
Bethesda, MD: 1999
|
|
17
|
Hodapp N: The ICRU Report 83: Prescribing,
recording, and reporting photon-beam intensity-modulated radiation
therapy (IMRT). Strahlenther Onkol. 188:97–99. 2012.(In German).
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Late effects consensus conference, .
RTOG/EORTC. Radiother Oncol. 35:5–7. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
U.S. Department of Health and Human
Services, . Common Terminology Criteria for Adverse Events v4.0
(CTCAE). https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5×7.pdfMay
31–2023
|
|
20
|
Lee AW, Ng WT, Chan LL, Hung WM, Chan CC,
Sze HC, Chan OS, Chang AT and Yeung RM: Evolution of treatment for
nasopharyngeal cancer-success and setback in the
intensity-modulated radiotherapy era. Radiother Oncol. 110:377–384.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ozdemir S, Akin M, Coban Y, Yildirim C and
Uzel O: Acute toxicity in nasopharyngeal carcinoma patients treated
with IMRT/VMAT. Asian Pac J Cancer Prev. 16:1897–1900. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McDowell LJ, Rock K, Xu W, Chan B, Waldron
J, Lu L, Ezzat S, Pothier D, Bernstein LJ, So N, et al: Long-term
late toxicity, quality of life, and emotional distress in patients
with nasopharyngeal carcinoma treated with intensity modulated
radiation therapy. Int J Radiat Oncol Biol Phys. 102:340–352. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fromme EK, Eilers KM, Mori M, Hsieh YC and
Beer TM: How accurate is clinician reporting of chemotherapy
adverse effects? A comparison with patient-reported symptoms from
the quality-of-life questionnaire C30. J Clin Oncol. 22:3485–3490.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Patrick DL, Ferketich SL, Frame PS, Harris
JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Ried
LD, et al: National institutes of health state-of-the-science
conference statement: Symptom management in cancer: Pain,
depression, and fatigue, july 15–17, 2002. J Natl Cancer Inst.
95:1110–1117. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jasmer KJ, Gilman KE, Muñoz Forti K,
Weisman GA and Limesand KH: Radiation-induced salivary gland
dysfunction: Mechanisms, therapeutics and future directions. J Clin
Med. 9:40952020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Alterio D, Gugliandolo SG, Augugliaro M,
Marvaso G, Gandini S, Bellerba F, Russell-Edu SW, De Simone I,
Cinquini M, Starzyńska A, et al: IMRT versus 2D/3D conformal RT in
oropharyngeal cancer: A review of the literature and meta-analysis.
Oral Dis. 27:1644–1653. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nutting CM, Morden JP, Harrington KJ,
Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay
M, et al: Parotid-sparing intensity modulated versus conventional
radiotherapy in head and neck cancer (PARSPORT): A phase 3
multicentre randomized controlled trial. Lancet Oncol. 12:127–136.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Miah AB, Gulliford SL, Bhide SA, Zaidi SH,
Newbold KL, Harrington KJ and Nutting CM: The effect of concomitant
chemotherapy on parotid gland function following head and neck
IMRT. Radiother Oncol. 106:346–351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chao KS, Deasy JO, Markman J, Haynie J,
Perez CA, Purdy JA and Low DA: A prospective study of salivary
function sparing in patients with head-and-neck cancers receiving
intensity-modulated or three-dimensional radiation therapy: Initial
results. Int J Radiat Oncol Biol Phys. 49:907–916. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ou X, Zhou X, Shi Q, Xing X, Yang Y, Xu T,
Shen C, Wang X, He X, Kong L, et al: Treatment outcomes and late
toxicities of 869 patients with nasopharyngeal carcinoma treated
with definitive intensity modulated radiation therapy: new insight
into the value of total dose of cisplatin and radiation boost.
Oncotarget. 6:38381–38397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li X, Kitpanit S, Lee A, Mah D, Sine K,
Sherman EJ, Dunn LA, Michel LS, Fetten J, Zakeri K, et al: Toxicity
profiles and survival outcomes among patients with nonmetastatic
nasopharyngeal carcinoma treated with intensity-modulated proton
therapy vs intensity-modulated radiation therapy. JAMA Netw Open.
4:e21132052021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bentzen SM, Dorr W, Anscher MS, Denham JW,
Hauer-Jensen M, Marks LB and Williams J: Normal tissue effects:
Reporting and analysis. Semin Radiat Oncol. 13:189–202. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vittrup AS, Kirchheiner K, Fokdal LU,
Bentze SM, Nout RA, Pötter R and Tanderup K: Reporting of late
morbidity after radiation therapy in large prospective studies: A
descriptive review of the current status. Int J Radiat Oncol Biol
Phys. 105:957–967. 2019. View Article : Google Scholar : PubMed/NCBI
|
